These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7924127)

  • 21. Bromfenac ophthalmic solution 0.07% dosed once daily for cataract surgery: results of 2 randomized controlled trials.
    Walters TR; Goldberg DF; Peace JH; Gow JA;
    Ophthalmology; 2014 Jan; 121(1):25-33. PubMed ID: 24021896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Screening of the new analgesic, bromfenac].
    Holland M; Schütz H
    Arzneimittelforschung; 1989 Aug; 39(8):831-2. PubMed ID: 2818671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation.
    Donnenfeld ED; Holland EJ; Stewart RH; Gow JA; Grillone LR;
    Ophthalmology; 2007 Sep; 114(9):1653-62. PubMed ID: 17445902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost.
    Kashiwagi K; Tsukahara S
    Br J Ophthalmol; 2003 Mar; 87(3):297-301. PubMed ID: 12598441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.
    Walters T; Raizman M; Ernest P; Gayton J; Lehmann R
    J Cataract Refract Surg; 2007 Sep; 33(9):1539-45. PubMed ID: 17720067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of bromfenac ophthalmic solution (Bromday) dosed once daily for postoperative ocular inflammation and pain.
    Henderson BA; Gayton JL; Chandler SP; Gow JA; Klier SM; McNamara TR;
    Ophthalmology; 2011 Nov; 118(11):2120-7. PubMed ID: 21762992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EFFECT OF BROMFENAC ON PAIN RELATED TO INTRAVITREAL INJECTIONS: A Randomized Crossover Study.
    Georgakopoulos CD; Tsapardoni F; Makri OE
    Retina; 2017 Feb; 37(2):388-395. PubMed ID: 27442130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isolation and identification of bromfenac glucoside from rat bile.
    Kirkman SK; Zhang MY; Horwatt PM; Scatina J
    Drug Metab Dispos; 1998 Jul; 26(7):720-3. PubMed ID: 9660857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Once daily dosing of bromfenac ophthalmic solution 0.09% for postoperative ocular inflammation and pain.
    Silverstein SM; Cable MG; Sadri E; Peace JH; Fong R; Chandler SP; Gow JA; Klier SM; McNamara TR;
    Curr Med Res Opin; 2011 Sep; 27(9):1693-703. PubMed ID: 21751945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic-pharmacodynamic relationships for analgesics.
    Suri A; Estes KS; Geisslinger G; Derendorf H
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):307-23. PubMed ID: 9266286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamic analysis of analgesic clinical trials using empirical methods.
    Liu CY; Sambol NC
    Pharm Res; 1995 Mar; 12(3):438-45. PubMed ID: 7617534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of bromfenac in healthy subjects after single oral administration of three different doses.
    Högger P; Rohdewald P
    Arzneimittelforschung; 1993 Oct; 43(10):1114-8. PubMed ID: 8267679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of topical indomethacin, bromfenac and nepafenac on lipopolysaccharide-induced ocular inflammation.
    Bucolo C; Marrazzo G; Platania CB; Romano GL; Drago F; Salomone S
    J Pharm Pharmacol; 2014 Jul; 66(7):954-60. PubMed ID: 24697218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent.
    Jones J; Francis P
    Expert Opin Pharmacother; 2009 Oct; 10(14):2379-85. PubMed ID: 19735215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of interaction between bromfenac and methotrexate in patients with rheumatoid arthritis.
    Gumbhir-Shah K; Cevallos WH; DeCleene SA; Korth-Bradley JM
    J Rheumatol; 1996 Jun; 23(6):984-9. PubMed ID: 8782127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of prostaglandin synthetase inhibitors on human preovulatory follicular fluid prostaglandin, thromboxane, and leukotriene concentrations.
    Priddy AR; Killick SR; Elstein M; Morris J; Sullivan M; Patel L; Elder M
    J Clin Endocrinol Metab; 1990 Jul; 71(1):235-42. PubMed ID: 2115045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparison of clinical effects of bromfenac sodium ophthalmic solution 0.1% versus glucocorticoids for post-LASEK usage].
    Chen S; Jiang Y; Yu C; Li Y
    Zhonghua Yan Ke Za Zhi; 2015 Jan; 51(1):45-50. PubMed ID: 25877710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Challenges in analgesic drug development.
    Hewitt DJ; Hargreaves RJ; Curtis SP; Michelson D
    Clin Pharmacol Ther; 2009 Oct; 86(4):447-50. PubMed ID: 19675542
    [No Abstract]   [Full Text] [Related]  

  • 39. The systemic safety of bromfenac ophthalmic solution 0.09%.
    Stewart RH; Grillone LR; Shiffman ML; Donnenfeld ED; Gow JA;
    J Ocul Pharmacol Ther; 2007 Dec; 23(6):601-12. PubMed ID: 18001250
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.